

**NOTICE OF NEW HAMPSHIRE MEDICAID
DRUG USE REVIEW BOARD
PUBLIC HEARING**

March 23, 2011

The New Hampshire Drug Use Review (DUR) Board invites you to attend a public hearing at 3:00 p.m., on March 23, 2011 at the Brown Building – Auditorium, 129 Pleasant Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing on March 23, 2011, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 3:00 p.m. and end no later than 4:00 p.m. The DUR meeting will begin at or before 4:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the March 23, 2011 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG USE REVIEW BOARD MEETING
March 23, 2011
Meeting Agenda**

I. Old Business

- a. Minutes – 10/25/10 review

II. New Business

1. Overview of Drug Utilization Patterns for New Hampshire Medicaid

- Prospective DUR Reports
- Utilization Reports
- Retrospective DUR Reports
- Behavioral Health Medications Utilization Review

2. Review of Current Preferred Drug List Therapeutic Classes with No Proposed Changes

Endocrinology

- Biguanides & Combinations
- Insulins
- Meglitinides
- 2nd Generation Sulfonylureas
- Thiazolidinediones and Combinations
- Alpha-Glucosidase Inhibitors

Ophthalmic

- Alpha 2 Adrenergic
- Beta Blocker Agents
- Carbonic Anhydrase Inhibitors
- Prostaglandins

Otic

- Quinolones and Combinations

Osteoporosis

- Biphosphonates

Analgesics

- Long Acting Narcotics
- Anti-inflammatory Non-Selective NSAIDS

3. Review of Current Clinical Prior Authorization Criteria

- Legend Topical NSAIDS
- Systemic Immunomodulators
- Antihyperkinesia
- Cymbalta®
- Suboxone®/Subutex®

III. Adjourn

Further information regarding the agenda items may be obtained after March 9, 2011, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.

Notice of intent to testify at the March 23, 2011 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.